First Header Logo Second Header Logo

Connection

Lance Miller to Cell Proliferation

This is a "connection" page, showing publications Lance Miller has written about Cell Proliferation.
Connection Strength

0.627
  1. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol. 2013 Apr 29; 14(4):R34.
    View in: PubMed
    Score: 0.367
  2. Chmielewski JP, Bowlby SC, Wheeler FB, Shi L, Sui G, Davis AL, Howard TD, D'Agostino RB, Miller LD, Sirintrapun SJ, Cramer SD, Kridel SJ. CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Mol Cancer Res. 2018 11; 16(11):1687-1700.
    View in: PubMed
    Score: 0.033
  3. Zhang Q, Wan M, Shi J, Horita DA, Miller LD, Kute TE, Kridel SJ, Kulik G, Sui G. Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation. J Mol Cell Biol. 2016 06; 8(3):232-43.
    View in: PubMed
    Score: 0.028
  4. Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB, Torti FM, Torti SV. IRP2 regulates breast tumor growth. Cancer Res. 2014 Jan 15; 74(2):497-507.
    View in: PubMed
    Score: 0.024
  5. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatology. 2013 Apr; 57(4):1469-83.
    View in: PubMed
    Score: 0.023
  6. Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV. JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer. Breast Cancer Res. 2012 May 23; 14(3):R85.
    View in: PubMed
    Score: 0.021
  7. Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. . 2012 Jul; 11(7):1488-99.
    View in: PubMed
    Score: 0.021
  8. Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G. Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol. 2012 May; 180(5):2120-33.
    View in: PubMed
    Score: 0.021
  9. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 2012 Jan 18; 104(2):133-46.
    View in: PubMed
    Score: 0.021
  10. Kannan N, Kang J, Kong X, Tang J, Perry JK, Mohankumar KM, Miller LD, Liu ET, Mertani HC, Zhu T, Grandison PM, Liu DX, Lobie PE. Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma. Neoplasia. 2010 Dec; 12(12):1041-53.
    View in: PubMed
    Score: 0.019
  11. Pinnix ZK, Miller LD, Wang W, D'Agostino R, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010 Aug 04; 2(43):43ra56.
    View in: PubMed
    Score: 0.019
  12. Wennmalm K, Miller LD, Bergh J. A gene signature in breast cancer. N Engl J Med. 2007 May 03; 356(18):1887-8; author reply 1887-8.
    View in: PubMed
    Score: 0.015
  13. Lin CY, Ström A, Li Kong S, Kietz S, Thomsen JS, Tee JB, Vega VB, Miller LD, Smeds J, Bergh J, Gustafsson JA, Liu ET. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res. 2007; 9(2):R25.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.